PapersFlow Research Brief
Chronic Obstructive Pulmonary Disease (COPD) Research
Research Guide
What is Chronic Obstructive Pulmonary Disease (COPD) Research?
Chronic Obstructive Pulmonary Disease (COPD) Research is the body of scientific work focused on the standardization, diagnosis, and management of COPD, including spirometry for lung function testing, global burden analysis, exacerbation frequency, and guidelines for treatment and prevention, while exploring links to systemic inflammation, comorbidities, and mortality.
This field encompasses 164,543 published works on COPD standardization, diagnosis, and management. Key efforts include spirometry standardization as detailed in "Standardisation of spirometry" by Miller et al. (2005), which provides combined ATS-ERS standards for lung function testing. Global strategies like "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease" by Vestbo et al. (2012) outline diagnosis and management approaches.
Topic Hierarchy
Research Sub-Topics
COPD Exacerbations
This sub-topic studies the frequency, triggers, severity, and outcomes of acute exacerbations in COPD patients using longitudinal cohort data and biomarkers. Researchers investigate microbial infections, environmental factors, and predictive models for exacerbation risk.
Spirometry Standardization
This sub-topic develops and validates protocols for spirometry performance, quality control, and reference equations across populations. Researchers address technical variability, maneuver acceptability, and multi-ethnic normative values.
COPD Global Burden
This sub-topic analyzes epidemiological trends, disability-adjusted life years, and mortality attributable to COPD using global health data like GBD studies. Researchers model projections, risk factor attributions, and disparities across regions.
COPD Comorbidities
This sub-topic examines the prevalence, interactions, and management of cardiovascular disease, osteoporosis, and depression alongside COPD. Researchers study shared inflammatory pathways, polypharmacy, and integrated care models.
COPD Pharmacological Management
This sub-topic evaluates inhaled bronchodilators, corticosteroids, and novel therapies for symptom control and exacerbation reduction via RCTs and meta-analyses. Researchers assess long-term efficacy, adherence, and subgroup responses.
Why It Matters
COPD research directly impacts clinical practice through standardized tools like spirometry, enabling accurate diagnosis as standardized in "Standardisation of spirometry" by Miller et al. (2005) and "Standardization of Spirometry, 1994 Update. American Thoracic Society." (1995). Guidelines from "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease" by Vestbo et al. (2012) and Pauwels et al. (2001) guide treatment and prevention worldwide. Recent advancements include NICE approval of the first targeted treatment for uncontrolled COPD, benefiting up to 30,000 people in England by reducing flare-ups by almost a third (NICE, 2026), and mepolizumab reducing annualized moderate or severe exacerbations in eosinophilic COPD patients on triple therapy (MATINEE trial, 2025). A $3.8M NIH grant funds early COPD biomarker research, while a $120,000 ALA/Chest grant supports interventions to reduce air pollution exposure in at-risk groups.
Reading Guide
Where to Start
"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease" by Vestbo et al. (2012), as it provides an accessible executive summary of GOLD strategies for COPD diagnosis and management, serving as an entry point before technical spirometry papers.
Key Papers Explained
"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease" by Pauwels et al. (2001) established foundational GOLD strategies, updated in Vestbo et al. (2012) with expanded contents on global health impacts. "Standardisation of spirometry" by Miller et al. (2005) builds diagnostic tools referenced in GOLD, complemented by "Interpretative strategies for lung function tests" by Pellegrino et al. (2005) for analysis. "Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations" by Quanjer et al. (2012) provides global equations integrating prior spirometry standards like Miller et al. (2005).
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
The "2026 GOLD Report and Pocket Guide" refines diagnosis and management strategies. Preprints explore precision medicine phenotypes (2025), treatment pipelines (2025), and cellular heterogeneity (2026). News highlights NICE-approved targeted therapies reducing flare-ups by a third (2026) and mepolizumab for eosinophilic COPD (2025), with NIH ($3.8M) and ALA/Chest ($120,000) grants funding biomarkers and interventions.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Global Strategy for the Diagnosis, Management, and Prevention ... | 2012 | American Journal of Re... | 16.0K | ✓ |
| 2 | Standardisation of spirometry | 2005 | European Respiratory J... | 15.4K | ✓ |
| 3 | ATS Statement | 2002 | American Journal of Re... | 10.4K | ✕ |
| 4 | The American-European Consensus Conference on ARDS. Definition... | 1994 | American Journal of Re... | 6.7K | ✕ |
| 5 | Standardization of Spirometry, 1994 Update. American Thoracic ... | 1995 | American Journal of Re... | 6.6K | ✕ |
| 6 | Global Strategy for the Diagnosis, Management, and Prevention ... | 2001 | American Journal of Re... | 6.5K | ✕ |
| 7 | Global Initiative for Chronic Obstructive Lung Disease | 2002 | Journal of Cardiopulmo... | 5.9K | ✕ |
| 8 | Interpretative strategies for lung function tests | 2005 | European Respiratory J... | 5.9K | ✓ |
| 9 | Multi-ethnic reference values for spirometry for the 3–95-yr a... | 2012 | European Respiratory J... | 5.6K | ✓ |
| 10 | Lung volumes and forced ventilatory flows | 1993 | European Respiratory J... | 5.2K | ✓ |
In the News
NICE approves first targeted treatment for uncontrolled COPD
The National Institute for Health and Care Excellence (NICE) has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up to 30,000 people...
New hope for people with breathing condition, COPD, as NICE approves innovative treatment
# New hope for people with breathing condition, COPD, as NICE approves innovative treatment Breakthrough therapy reduces flare-ups by almost a third and could ease pressure on NHS hospitals. News26...
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
Treatment with mepolizumab led to a lower annualized rate of moderate or severe exacerbations when added to background triple inhaled therapy among patients with COPD and an eosinophilic phenotype....
$3.8M NIH grant will fund research into potential early COPD ...
# $3.8M NIH grant will fund research into potential early COPD biomarker # $3.8M NIH grant will fund research into potential early COPD biomarker Aug. 14, 2025 By Blair Willis, U of A Health Sciences
ALA/Chest Grant Issued for COPD Research | RT
1. **Grant Awarded** — The American Lung Association and American College of Chest Physicians awarded Dr Crystal M. North a two-year, $120,000 grant to study educational interventions that reduce a...
Code & Tools
This repository contains code developed as part of the following paper: "Deep Learning for Detecting and Early Predicting Chronic Obstructive Pulmo...
## General Information Official PyTorch implementation for paper **_cOOpD: Reformulating COPD classification on chest CT scans as anomaly detectio...
proposed an efficient COPD severity classification framework using variational mode decomposition (VMD); which involves four major stages: (a) prep...
`Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-...
Abstract
Recent Preprints
2026 GOLD Report and Pocket Guide
# 2026 GOLD Report and Pocket Guide ### GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD: 2026 Report Evidence-based strategy document for COPD diagnosis, management, and prevention...
Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysi...
Toward precision medicine in COPD: phenotypes, endotypes, biomarkers, and treatable traits
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by diverse clinical manifestations, pathophysiological mechanisms, and therapeutic responses. This review expl...
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lungs that affects about 10% of the adult population and is currently the third leading global cause of death. COPD i...
Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a leading cause of death in the United States 1 . Although defined by persistent airflow limitation, COPD presents with broad variation in the severi...
Latest Developments
Recent developments in COPD research as of February 2026 include a focus on earlier diagnosis using algorithms for case-finding (published November 2025), updated strategies for exacerbation management and case identification (January 2026), and emerging biologic treatments such as tezepelumab and drugs like mepolizumab and dupilumab targeting eosinophilic inflammation (January 2026, May 2025, June 2024) (pulmonologyadvisor, chestphysician.org, nejm.org, labiotech.eu).
Sources
Frequently Asked Questions
What is the role of spirometry in COPD diagnosis?
Spirometry measures lung function through forced vital capacity and forced expiratory volume, as standardized in "Standardisation of spirometry" by Miller et al. (2005). This ATS-ERS task force document covers instrument setup, procedure, and quality control for accurate testing. It recommends adjustments for maneuver velocity to ensure complete respiratory measurements.
How do GOLD guidelines support COPD management?
"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease" by Vestbo et al. (2012) presents the GOLD strategy updated since 2001 for COPD diagnosis and management. The document summarizes key contents for global health application. Earlier versions like Pauwels et al. (2001) laid foundational strategies.
What reference values are used for lung function tests?
"Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations" by Quanjer et al. (2012) derives equations from over 160,000 data points across 72 centers in 33 countries. These provide continuous prediction equations and lower limits of normal for global spirometric indices. The work supports the European Respiratory Society Global Lung Function Initiative.
What interpretative strategies apply to lung function tests?
"Interpretative strategies for lung function tests" by Pellegrino et al. (2005) from the ATS-ERS Task Force emphasizes selecting appropriate reference values and lower normal limits. It lists available reference studies for interpretation. The strategies aid in assessing obstruction and restriction patterns.
What defines lung volumes in spirometry?
"Lung volumes and forced ventilatory flows" by Quanjer et al. (1993) subdivides lung volumes into static and dynamic types. Static volumes use complete respiratory maneuvers with adjusted velocity. Dynamic measurements occur during fast breathing.
What is the current status of COPD guidelines?
The "2026 GOLD Report and Pocket Guide" updates the evidence-based strategy for COPD prevention, diagnosis, and management with literature citations. It includes a summary of changes from prior versions. This reflects ongoing refinements building on Vestbo et al. (2012).
Open Research Questions
- ? How can phenotypes, endotypes, biomarkers, and treatable traits enable precision medicine in heterogeneous COPD?
- ? What new treatments in the current pipeline address dynamic gene-environment interactions in COPD?
- ? What aberrant cellular communities drive heterogeneity in COPD obstruction severity, symptoms, and exacerbations?
- ? How effective are educational interventions in reducing air pollution exposure for COPD at-risk populations?
- ? Can deep learning on spirogram time series enable early COPD prediction from datasets like UK Biobank?
Recent Trends
The field sees active guideline updates with the "2026 GOLD Report and Pocket Guide".
2025NICE approved a targeted COPD treatment for up to 30,000 patients, cutting flare-ups by nearly a third , alongside mepolizumab efficacy in eosinophilic phenotypes (2025).
2026Grants include $3.8M NIH for early biomarkers and $120,000 ALA/Chest for air pollution interventions (2025).
2025Preprints address precision medicine, pipelines, and cellular communities.
Research Chronic Obstructive Pulmonary Disease (COPD) Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chronic Obstructive Pulmonary Disease (COPD) Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers